Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Abstract

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

1 - 71 . (canceled) 
     
     
         72 . A composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities. 
     
     
         73 . The composition of  claim 72 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities. 
     
     
         74 . The composition of  claim 72 , wherein the composition shows no tyrosinase inhibition activity relative to a kojic acid control. 
     
     
         75 . The composition of  claim 72 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof. 
     
     
         76 . The composition of  claim 72 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier. 
     
     
         77 . The composition of  claim 72 , wherein the composition is administered topically, by aerosol, by suppository, intradermically, intramuscularly or intravenously. 
     
     
         78 . The composition of  claim 72 , wherein the composition is formulated for topical administration. 
     
     
         79 . The composition of  claim 72 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol. 
     
     
         80 . The composition of  claim 72 , wherein the composition comprises about 0.5% by total weight of bakuchiol. 
     
     
         81 . The composition of  claim 72 , wherein the composition further comprises salicylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         82 . A composition comprising synthetic bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities. 
     
     
         83 . The composition of  claim 82 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities. 
     
     
         84 . The composition of  claim 82 , wherein the composition shows no tyrosinase inhibition activity relative to a kojic acid control. 
     
     
         85 . The composition of  claim 82 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof. 
     
     
         86 . The composition of  claim 82 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier. 
     
     
         87 . The composition of  claim 82 , wherein the composition is administered topically, by aerosol, by suppository, intradermically, intramuscularly or intravenously. 
     
     
         88 . The composition of  claim 82 , wherein the composition is formulated for topical administration. 
     
     
         89 . The composition of  claim 82 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol. 
     
     
         90 . The composition of  claim 82 , wherein the composition comprises about 0.5% by total weight of bakuchiol. 
     
     
         91 . The composition of  claim 82 , wherein the composition further comprises salicylic acid or a pharmaceutically acceptable salt thereof.